| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anthocyanins — Anthocyanins (ACNs) are a structurally diverse class of water-soluble flavonoid pigments (glycosylated anthocyanidins) abundant in berries, purple/red grapes, cherries, red cabbage, and other deeply colored plants. They function as pleiotropic redox- and inflammation-modulating polyphenols with context-dependent signaling effects that can shift from antioxidant/anti-inflammatory tone at nutritionally relevant exposures to stress-signaling/pro-apoptotic effects in tumor models at higher concentrations. Classification: dietary polyphenols (flavonoids; anthocyanidin O-glycosides). Standard abbreviations: ACNs; often specified as C3G (cyanidin-3-O-glucoside) or as “total anthocyanins.” A key translation nuance is that circulating parent ACNs are typically low and transient, while phase-II conjugates and gut microbiota–derived phenolic acids (e.g., protocatechuic acid from cyanidin glycosides) plausibly mediate a meaningful fraction of systemic biology. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral bioavailability of intact parent anthocyanins is generally modest with rapid appearance and clearance; extensive phase-II metabolism (glucuronidation/sulfation/methylation) and prominent gut microbiota catabolism generate phenolic acid metabolites that may dominate systemic exposure. Local gastrointestinal exposures can be substantially higher than plasma levels, making “GI-local” mechanisms more plausible than “systemic parent-compound” mechanisms for many endpoints. In-vitro vs systemic exposure relevance: Many anticancer in-vitro studies use ~10–100+ µM parent anthocyanins/extract equivalents, which often exceed achievable circulating parent anthocyanin concentrations after dietary intake; therefore, mechanistic claims that require high micromolar parent exposure should be treated as (high concentration only) unless supported by metabolite biology or GI-local relevance. Clinical evidence status: Human evidence is strongest for cardiometabolic and inflammation-related biomarkers (multiple RCTs/meta-analyses). For cancer, evidence is predominantly preclinical and epidemiologic/biomarker-level in humans; there is no established oncology indication or regulatory approval as an anticancer drug. For cognition/brain aging, small RCTs with anthocyanin-rich foods/supplements show signal in select domains, but overall evidence remains exploratory. "Anthocyanins are a class of water‐soluble flavonoids, which show a range of pharmacological effects, such as prevention of cardiovascular disease, obesity control and antitumour activity. Their potential antitumour effects are reported to be based on a wide variety of biological activities including antioxidant; anti‐inflammation; anti‐mutagenesis; induction of differentiation; inhibiting proliferation by modulating signal transduction pathways, inducing cell cycle arrest and stimulating apoptosis or autophagy of cancer cells; anti‐invasion; anti‐metastasis; reversing drug resistance of cancer cells and increasing their sensitivity to chemotherapy."Anthocyanins are flavonoid pigments with multi-target pleiotropic effects in cancer models, primarily through modulation of ROS balance, NF-κB signaling, PI3K/Akt/mTOR inhibition, apoptosis induction, and anti-angiogenic activity. Their effects are often context-dependent and dose-dependent: low physiologic exposures tend to support antioxidant and anti-inflammatory tone, whereas higher concentrations in vitro can induce oxidative stress and apoptosis in tumor cells. They also influence tumor microenvironment dynamics including VEGF signaling, MMP activity, and inflammatory cytokines. Bioavailability is modest, and metabolites (phenolic acids) likely contribute significantly to biological effects. Evidence in humans remains supportive but not definitive. • Anthocyanins are a class of water-soluble flavonoid pigments responsible for the red, purple, and blue hues in many fruits, vegetables, and flowers (e.g., berries, red grapes, and eggplants). • Anthocyanins can effectively scavenge free radicals and reduce oxidative stress, thereby protecting cellular components like DNA, lipids, and proteins from oxidative damage—a factor linked to carcinogenesis. • Their antioxidant capacity helps in neutralizing reactive oxygen species (ROS), which can otherwise promote mutations and tumor initiation. • Anthocyanins have been shown to inhibit pro-inflammatory cytokines (e.g., TNF-α, IL-6) and enzymes (e.g., COX-2), reducing the inflammatory signals associated with cancer progression. • They may modulate pathways such as NF-κB, MAPK, and PI3K/Akt, contributing to the downregulation of genes involved in survival and proliferation of cancer cells. • Anthocyanins have been found to inhibit the formation of new blood vessels (angiogenesis) essential for tumor growth and metastatic spread. Anthocyanins: ranked cancer-relevant pathway effects
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr Anthocyanins and Alzheimer’s disease — Anthocyanin-rich foods/supplements have small-human-trial signals suggesting modest improvements in selected cognitive domains and/or brain function proxies in at-risk or impaired cohorts, plausibly mediated through vascular/inflammatory tone, oxidative stress buffering, and microbiome–metabolite signaling (rather than sustained high circulating parent anthocyanins). Overall, evidence remains exploratory and heterogeneous across preparations, doses, and endpoints. Clinical evidence status: Small RCTs/pilot trials (food-based and some purified preparations) with mixed but promising signals; not an established disease-modifying therapy. Anthocyanins: non-cancer mechanisms relevant to Alzheimer’s disease
|
| Source: |
| Type: |
| Once the cancer has begun, NO seems to play a protumoral role rather than antitumoral one as the concentration required to cause tumor cell cytotoxicity cannot be achieved by cancer cells. The mechanistic roles of nitric oxide (NO) during cancer progression have been important considerations since its discovery as an endogenously generated free radical. Nonetheless, the impacts of this signaling molecule can be seemingly contradictory, being both pro-and antitumorigenic, which complicates the development of cancer treatments based on the modulation of NO fluxes in tumors. At a fundamental level, low levels of NO drive oncogenic pathways, immunosuppression, metastasis, and angiogenesis, while higher levels lead to apoptosis and reduced hypoxia and also sensitize tumors to conventional therapies. However, clinical outcome depends on the type and stage of the tumor as well as the tumor microenvironment. Nitric oxide is generated by three main nitric oxide synthase isoforms: neuronal (nNOS), endothelial (eNOS), and inducible (iNOS). – In many cancers, especially under inflammatory conditions, iNOS expression is upregulated. In contrast, eNOS levels may also be altered in cancers such as breast or prostate cancer. • Expression Patterns in Tumors: – Elevated iNOS expression is commonly observed in various tumor types (e.g., colon, breast, lung, and melanoma) and is often associated with an inflammatory microenvironment. – Changes in eNOS and nNOS expression have also been reported and may contribute to angiogenesis and tumor blood flow regulation. |
| 3972- | ACNs, | Recent Research on the Health Benefits of Blueberries and Their Anthocyanins |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:31 Target#:563 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid